Skip to main content
. 2019 Nov 26;51(5):323–329. doi: 10.4103/ijp.IJP_743_17

Table 2.

Overall drug utilization in total number of prescriptions of the study population

Drugs prescribed In-hospital (n=1120) At discharge (n=877)
Cardiac drugs
 Antiplatelets 964 (86.07) 716 (81.64)
 Anticoagulants 623 (55.62) 24 (27.37)
 Thrombolytics 133 (11.87) 0
 Antianginals 638 (56.96) 347 (39.58)
 Statins 903 (80.62) 672 (76.62)
 ACE inhibitors 795 (70.98) 568 (64.77)
 Angiotensin receptor blocker 12 (1.07) 11 (1.25)
 Beta blockers 471 (42.05) 566 (64.54)
 Alpha and beta blockers 225 (20.09) 192 (21.89)
 Diuretics 738 (65.89) 483 (55.07)
 Antiarrhythmics 47 (4.2) 13 (1.48)
 Calcium channel blockers 121 (10.8) 71 (8.1)
 Inotropes 356 (31.79) 134 (15.28)
Noncardiac drugs
 Oxygen 467 (41.7) 0
 Bronchodilators 226 (20.18) 47 (5.36)
 Intravenous fluids 381 (34.02) 0
 Antidiabetics 180 (16.07) 144 (16.42)
 Antibiotics 433 (38.66) 139 (15.85)
 Centrally acting drugs 183 (16.34) 43 (4.9)
 Antiulcer drugs 938 (83.75) 616 (70.24)
 Antihistamines 171 (15.27) 5 (0.57)
 Laxatives 127 (11.34) 11 (1.25)
 Mucokinetics 134 (11.96) 23 (2.62)
 Antiemetics 110 (9.82) 12 (1.37)
 Antidiarrheals 38 (3.39) 4 (0.46)
 Analgesic, anti-inflammatory, and muscle relaxant 86 (7.68) 84 (9.58)
 Thyroid drugs 11 (0.09) 12 (1.37)
 Vitamin supplements 298 (26.61) 388 (44.24)
 Overall electrolyte 394 (35.18) 131 (14.94)
 Erectile dysfunction drugs 48 (4.29) 37 (4.22)
 Antivertigo 15 (1.34) 5 (0.57)
 Ursodeoxycholic acid 11 (0.09) 5 (0.57)
 Benign prostatic hyperplasia drug 1 (0.01) 1 (0.1)

ACE=Angiotensin-converting enzyme